Altamira Therapeutics Quote - CYTO

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.91

Bid

0.8781

Offer

1.50

Volume

70,008

0.864 Day's Range 0.94

0.79 52 Week Range 17.20

Market Cap

2.585M

Previous Close

0.92

Open

0.94

Last Trade

165

0.91

(formt)

Last Trade Time

Financial Volume

US$ 63,365

VWAP

0.905104

Average Volume (3m)

498,290

Shares Outstanding

2,840,524

Dividend Yield

PE Ratio

-2.23

Earnings Per Share (EPS)

-1.36

Revenue

158k

Net Profit

-3.87M

Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore TM / SemaPhore TM delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-4... Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore TM / SemaPhore TM delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Show more

Sector

Med, Dental, Hosp Eq-whsl

Industry

Med, Dental, Hosp Eq-whsl

Website

altamiratherapeutics.com

Headquarters

Basel, Che

Founded

Altamira Therapeutics Ltd is listed in the Med, Dental, Hosp Eq-whsl sector of the NASDAQ with ticker CYTO. The last closing price for Altamira Therapeutics was US$0.92. Over the last year, Altamira Therapeutics shares have traded in a share price range of US$ 0.79 to US$ 17.20.

Altamira Therapeutics currently has 2,840,524 shares in issue. The market capitalisation of Altamira Therapeutics is US$2.61 million. Altamira Therapeutics has a price to earnings ratio (PE ratio) of -2.23.

Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11

Hamilton, Bermuda, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery...

Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark

Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024Exclusive distribution agreement extended to also include Sweden and...

Form F-1 - Registration statement for certain foreign private issuers

Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances

Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Independent analytical testing of Bentrio for > 230 prohibited substances of WADA list found none of themOutcome further confirms...

Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models

Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Treatment with ZbtbB46 mRNA nanoparticles based on Altamira’s SemaPhore™ delivery technology results in significant reduction in tumor growth...

Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles

Hamilton, Bermuda, July 19, 2024 (GLOBE NEWSWIRE) -- Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0.91	0.94	0.85	30023	0.90051318	CS
4	-0.09	-9	1	1.3344	0.831	1098768	1.00380553	CS
12	-0.34	-27.2	1.25	1.53	0.79	498290	1.04790265	CS
26	-1.15	-55.8252427184	2.06	3.49	0.79	1216703	1.85237824	CS
52	-6.09	-87	7	17.2	0.79	4692772	6.3753004	CS
156	-1071.09	-99.9151119403	1072	1332	0.79	2554003	171.26214186	CS
260	-1171.09	-99.9223549488	1172	1548	0.79	2482751	182.55300725	CS

Symbol	Price	Vol.
WHLRWheeler Real Estate Investment Trust Inc	US$ 10.52 (154.11%)	78.05M
BLMZBloomZ Inc	US$ 1.76 (117.82%)	138.64M
SMXTSolarMax Technology Inc	US$ 1.49 (39.25%)	2.38M
BENFBeneficient	US$ 2.045 (36.33%)	111.46M
WLGSWang and Lee Group Inc	US$ 0.75 (29.67%)	227.2k
NBSTWNewbury Street Acquisition Corporation	US$ 0.0503 (-32.93%)	5.7k
AZIAutozi Internet Technology Global Ltd	US$ 1.28 (-29.28%)	576.57k
RENTRent the Runway Inc	US$ 10.90 (-27.72%)	592.68k
SHPHShuttle Pharmaceuticals Holdings Inc	US$ 1.63 (-24.88%)	941.36k
IVPInspire Veterinary Partners Inc	US$ 0.8799 (-24.79%)	7.38M
NVDANVIDIA Corporation	US$ 102.83 (-4.09%)	414.11M
SQQQProShares UltraPro Short QQQ	US$ 9.72 (8.00%)	235.8M
XPONExpion360 Inc	US$ 0.0683 (-4.74%)	164.86M
WTOUTime Limited	US$ 0.068 (5.10%)	151.89M
BLMZBloomZ Inc	US$ 1.76 (117.82%)	145.44M

Symbol

Price

Vol.